Rollover Study for Continuing NBI-98854 Administration in Pediatric Subjects With Tourette Syndrome
Status:
Terminated
Trial end date:
2019-02-18
Target enrollment:
Participant gender:
Summary
This is an open-label, rollover study to collect long-term safety, tolerability, and
investigator- and participant-reported pharmacodynamic (PD) data after chronic administration
of NBI-98854 in pediatric participants with Tourette Syndrome (TS), as well as to provide
open-label access to NBI-98854 for the treatment of TS for pediatric participants who have
taken part in a Phase 2 NBI-98854 study.